Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Martha Kingman"'
Autor:
Melisa Wilson, Jennifer Keeley, Martha Kingman, Susanne McDevitt, Jacqueline Brewer, Frances Rogers, Wendy Hill, Zachary Rideman, Meredith Broderick
Publikováno v:
Pulmonary Circulation, Vol 12, Iss 3, Pp n/a-n/a (2022)
Abstract Performing longitudinal and consistent risk assessments for patients with pulmonary arterial hypertension (PAH) is important to help guide treatment decisions to achieve early on and maintain a low‐risk status and improve patient morbidity
Externí odkaz:
https://doaj.org/article/b4832835b60f47ec8d14c87d71e8d809
Publikováno v:
Pulmonary Circulation, Vol 10 (2020)
Practice guidelines suggest that treatment decisions in pulmonary arterial hypertension be informed by periodic assessment of patients’ clinical risk. Several tools, well validated for risk discrimination, such as the Registry to Evaluate Early and
Externí odkaz:
https://doaj.org/article/ddd874a7c81a4b76977898fa66afa572
Publikováno v:
Pulmonary Therapy, Vol 4, Iss 1, Pp 13-27 (2018)
Abstract Fluid volume management in patients with pulmonary arterial hypertension (PAH) is essential in preventing right ventricular failure. Volume overload may be caused by disease progression, indiscretion of dietary sodium and fluid intake, or me
Externí odkaz:
https://doaj.org/article/81bf556d66c44dafad8cd9d2500e8534
Publikováno v:
Pulmonary Circulation
Pulmonary Circulation, Vol 10 (2020)
Pulmonary Circulation, Vol 10 (2020)
Practice guidelines suggest that treatment decisions in pulmonary arterial hypertension be informed by periodic assessment of patients' clinical risk. Several tools, well validated for risk discrimination, such as the Registry to Evaluate Early and L
Autor:
Martha Kingman, Fernando Torres, Colin Andrew Hinkamp, Trushil G. Shah, O. Igenoza, S. Harden, Sonja Bartolome, Kelly Chin
Publikováno v:
B56. PULMONARY HYPERTENSION CLINICAL TRIALS ENDEAVOR SAFETY, COMBINATION WHAT ELSE?.
Autor:
Samuel Clark Berngard, Sandra Lombardi, Martha Kingman, Timothy M. Fernandes, Maribeth Duncan
Publikováno v:
Respiratory Medicine. 143:139-146
The availability of new medications has improved exercise capacity, enhanced quality of life, and extended time to clinical worsening in patients with pulmonary arterial hypertension (PAH). For many of these medications, careful individualized dose t
Autor:
Natalie Kitterman, Traci Stewart, Debra Zupancic, Martha Kingman, Melisa Wilson, Judy Germani
Publikováno v:
Pulmonary Therapy. 3:31-43
Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are subtypes of pulmonary hypertension—a rare, life-threatening condition defined by chronically elevated pulmonary artery pressure. Treatment goals inc
Autor:
Martha Kingman, Trushil G. Shah, O. Igenoza, Kelly Chin, S. Harden, Fernando Torres, Sonja Bartolome
Publikováno v:
C51. CLOSER TO THE HEART: UPDATE ON APPROVED THERAPIES FOR PAH.
Autor:
Sean M, Studer, Martha, Kingman, Luis, Calo, H Eric, Cannon, Jeffrey D, Dunn, Thomas, James, Sonya J, Lewis, Robert J, Gilkin, Janis A, Pruett
Publikováno v:
The American journal of managed care. 23
A roundtable panel of national and regional managed care decision makers and providers met to discuss pulmonary arterial hypertension (PAH) and strategies for management. As a rare, complex disease with high economic costs and potentially devastating
Autor:
Martha Kingman, Robin Hohsfield, Mary Bartlett, Joy Beckmann, Christine Archer-Chicko, Sandra Lombardi
Publikováno v:
Pulmonary Circulation
Therapies that target the prostacyclin pathway are considered effective, yet are complex to dose and may cause dose-limiting side effects for patients with pulmonary arterial hypertension (PAH). Careful side effect management and the ability to disce